Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone702-835-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$128.37 million
Profitability
Miscellaneous
Employees215
OptionableOptionable
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.10. The biotechnology company had revenue of $25.27 million for the quarter, compared to the consensus estimate of $25.73 million. Spectrum Pharmaceuticals had a negative net margin of 91.56% and a negative return on equity of 27.72%. The company's quarterly revenue was down 30.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. View Spectrum Pharmaceuticals' Earnings History.
When is Spectrum Pharmaceuticals' next earnings date?
What price target have analysts set for SPPI?
2 equities research analysts have issued 1 year price objectives for Spectrum Pharmaceuticals' shares. Their forecasts range from $21.00 to $40.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $30.50 in the next twelve months. This suggests a possible upside of 179.6% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.
What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.
What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)
- 2. According to Zacks Investment Research, "Spectrum Pharma is progressing well with its lead pipeline candidate, Rolontis, and a regulatory application is expected to be filed in 2018. A potential approval will boost the prospects of the company. However, Spectrum has faced regulatory setbacks in the past including rejection of regulatory application for Qapzola seeking approval for bladder cancer in the United States. Additional regulatory/development setbacks could affect the stock. However, out-licensing agreements for a number of products will allow Spectrum to focus on the development of its pipeline candidates. Spectrum’s shares have outperformed the industry so far this year. However, Spectrum's low product sales amid strong competition is a concern. Loss estimates have remained stable ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (11/16/2018)
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
News headlines about SPPI stock have trended somewhat negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include FibroGen (FGEN), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), Emergent Biosolutions (EBS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM) and Akcea Therapeutics (AKCA).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
- Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
- Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
- Mr. Keith M. McGahan J.D., L.L.M., Chief Legal Officer & Corp. Sec.
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.04%), State of Alaska Department of Revenue (0.03%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Which major investors are selling Spectrum Pharmaceuticals stock?
SPPI stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Which major investors are buying Spectrum Pharmaceuticals stock?
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $10.91.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $1.12 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.
What is Spectrum Pharmaceuticals' official website?
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
